Abstract

BackgroundArtemisinin-based combination therapy (ACT), used to treat uncomplicated malaria cases, is one of the main strategies of malaria control and elimination. One of the main objectives of the Benin National Malaria Control Program’s (NMCP) strategic plan is to ensure that at least 80% of uncomplicated malaria is treated with ACT within 24 h. Therefore, it was of great interest to measure whether the country case management of fever amongst children under five, adhered to the NMCP’s strategic plan and look into the barriers to the use of ACT.MethodsA cross-sectional survey based on a cluster and multi-stage sampling was conducted in two rural health districts in Benin. We recruited 768 and 594 children under five years were included in the northern and in the southern respectively. Data was collected on the general use of ACT and on the correct use of ACT that adheres to the NMCP’s strategy, as well as the barriers that prevent the proper management of fever amongst children. To assess the certain predictors of ACT usage, logistic regression was used, while taking into account the cluster random effect.ResultsAmong febrile children aged 6 to 59 months, 20.7% in the south and 33.9% in north received ACT. The correct use of ACT, was very low, 5.8% and in southern and 8.6% northern areas. Caregivers who received information on ACT were 3.13 time more likely in the south and 2.98 time more likely in the north to give ACT to their feverish child, PPR = 3.13[1.72–4.15] and PPR = 2.98 [2.72–3.11] respectively. Chloroquine and quinine, other malaria treatments not recommended by NMCP, were still being used in both areas: 12.3 and 3.3% in the south and 11.4 and 3.0% in the north.ConclusionIn Benin, the use and the correct use of ACT for febrile children remains low. The study also showed that having received information about the use of ACT is positively associated with the use of ACT. This point highlights the fact that efforts may not have been sufficiently integrated with social communication, which should be based on the behavioural determinants of populations.

Highlights

  • Artemisinin-based combination therapy (ACT), used to treat uncomplicated malaria cases, is one of the main strategies of malaria control and elimination

  • We investigated the correct use of ACT based on National Malaria Control Program (NMCP)/World Health Organization (WHO) recommended treatment, the anti-malarial drugs commonly used, the sale agency of ACT and the declared reason of the non-use of ACT

  • Use of ACT To overcome the challenges of anti-malarial drug resistance and improve treatment efficacy, WHO expert panels have recommended since 2001 the use of a fixeddose of ACT as first-line treatment for uncomplicated P. falciparum malaria [34, 35]

Read more

Summary

Introduction

Artemisinin-based combination therapy (ACT), used to treat uncomplicated malaria cases, is one of the main strategies of malaria control and elimination. Artemisinin-based combination therapy (ACT) is used for the treatment of malaria cases in areas where Plasmodium species are resistant to certain anti-malarial drugs. A large proportion of fever cases, especially in Africa, are treated as cases of malaria without parasitological confirmation (50 to 90%) [1, 3,4,5] and most febrile children under five years of age are taken care of at home [6]. The IMCI strategy focuses on malaria, diarrhoea, pneumonia, and malnutrition diagnosis and treatment [8] This approach requires malaria parasitological diagnosis before treatment with ACT [9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call